Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

Clin Cancer Res (2005) 11 (21): 7872–7878.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Utilising high-dimensional data in randomised clinical trials: A review of methods and practice
  • Svetlana Cherlin
  • Theophile Bigirumurame
  • Michael J Grayling
  • Jérémie Nsengimana
  • Luke Ouma
  • Aida Santaolalla
  • Fang Wan
  • S Faye Williamson
  • James MS Wason
Research Methods in Medicine & Health Sciences (2024) 5 (4): 110.
Finding the best subgroup with differential treatment effect with multiple outcomes
  • Beibo Zhao
  • Jason Fine
  • Anastasia Ivanova
Statistics in Medicine (2024) 43 (13): 2487.
A pseudo-response approach to constructing confidence intervals for the subset of patients expected to benefit from a new treatment
  • Wei Liu
  • Zhiwei Zhang
  • Zonghui Hu
  • Ping Xu
  • Calvin J Cohen
Journal of the Royal Statistical Society Series C: Applied Statistics (2024) 73 (2): 522.
Cross-validated risk scores adaptive enrichment (CADEN) design
  • Svetlana Cherlin
  • James M.S. Wason
Contemporary Clinical Trials (2024) 144: 107620.
Toward Precision in Critical Care Research: Methods for Observational and Interventional Studies
  • Emma J. Graham Linck
  • Ewan C. Goligher
  • Matthew W. Semler
  • Matthew M. Churpek
Critical Care Medicine (2024) 52 (9): 1439.
New insights into adaptive enrichment designs
  • Alessandro Baldi Antognini
  • Rosamarie Frieri
  • Maroussa Zagoraiou
Statistical Papers (2023) 64 (4): 1305.
Inference on subgroups identified based on a heterogeneous treatment effect in a post hoc analysis of a clinical trial
  • Beibo Zhao
  • Anastasia Ivanova
  • Jason Fine
Clinical Trials (2023) 20 (4): 370.
A gated group sequential design for seamless Phase II/III trial with subpopulation selection
  • Guanhong Miao
  • Jason J. Z. Liao
  • Jing Yang
  • Keaven Anderson
BMC Medical Research Methodology (2023) 23 (1)
Using biomarkers to allocate patients in a response-adaptive clinical trial
  • H. Jackson
  • S. Bowen
  • T. Jaki
Communications in Statistics - Simulation and Computation (2023) 52 (12): 5946.
Exploring alternative approaches to precision medicine through genomics and artificial intelligence – a systematic review
  • Hassan Mumtaz
  • Muhammad Saqib
  • Sidra Jabeen
  • Muhammad Muneeb
  • Wajiha Mughal
  • Hassan Sohail
  • Myra Safdar
  • Qasim Mehmood
  • Muhammad Ahsan Khan
  • Syed Muhammad Ismail
Frontiers in Medicine (2023) 10
Bayesian Sequential Design for Identifying and Ranking Effective Patient Subgroups in Precision Medicine in the Case of Counting Outcome Data with Inflated Zeros
  • Valentin Vinnat
  • Djillali Annane
  • Sylvie Chevret
Journal of Personalized Medicine (2023) 13 (11): 1560.
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers
  • Yeonhee Park
  • Suyu Liu
  • Peter F. Thall
  • Ying Yuan
Biometrics (2022) 78 (1): 60.
Clinical Trials for Personalized Medicine: Design and Data Analysis
  • Shigeyuki Matsui
Japanese Journal of Biometrics (2022) 43 (1): 97.
Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials
  • Weidong Zhang
  • Sunhee Ro
  • Qi Jiang
  • Xiaoyun Li
  • Rong Liu
  • Chengxing ‘Cindy’ Lu
  • Olga Marchenko
  • Jing Zhao
  • Zhenzhen Xu
Therapeutic Innovation & Regulatory Science (2022) 56 (4): 552.
A two‐stage adaptive clinical trial design with data‐driven subgroup identification at interim analysis
  • Sarah E. Johnston
  • Ilya Lipkovich
  • Alex Dmitrienko
  • Yan Daniel Zhao
Pharmaceutical Statistics (2022) 21 (5): 1090.
A Contextual-Bandit-Based Approach for Informed Decision-Making in Clinical Trials
  • Yogatheesan Varatharajah
  • Brent Berry
Life (2022) 12 (8): 1277.
Optimal Biomarker Cutoff Identification and Validation
  • Jianan Hui
  • Wenchuan Guo
Statistics in Biosciences (2022) 14 (2): 352.
A likely responder approach for the analysis of randomized controlled trials
  • Eugene Laska
  • Carole Siegel
  • Ziqiang Lin
Contemporary Clinical Trials (2022) 114: 106688.
Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials
  • Kiichiro Toyoizumi
  • Shigeyuki Matsui
Statistics in Medicine (2022) 41 (26): 5276.
A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation
  • Zheyu Wang
  • Fujun Wang
  • Chenguang Wang
  • Jianliang Zhang
  • Hao Wang
  • Li Shi
  • Zhuojun Tang
  • Gary L. Rosner
Statistics in Biopharmaceutical Research (2022) 14 (4): 568.
Sample size re-estimation in adaptive enrichment design
  • Ruitao Lin
  • Zhao Yang
  • Ying Yuan
  • Guosheng Yin
Contemporary Clinical Trials (2021) 100: 106216.
The optimal design of clinical trials with potential biomarker effects: A novel computational approach
  • Yitao Lu
  • Julie Zhou
  • Li Xing
  • Xuekui Zhang
Statistics in Medicine (2021) 40 (7): 1752.
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study
  • Hiroya Taniguchi
  • Takayuki Yoshino
  • Kensei Yamaguchi
  • Kentaro Yamazaki
  • Andrew B. Nixon
  • Josep Tabernero
  • Eric Van Cutsem
  • Kim R. Robling
  • Paolo B. Abada
  • Rebecca R. Hozak
  • Robert Siegel
  • Jeffrey A. Fill
  • Sameera Wijayawardana
  • Richard A. Walgren
  • Brendan Giles
  • Abby Jones
  • Kelly R. Pitts
  • Nora Drove
  • Kei Muro
Current Medical Research and Opinion (2021) 37 (10): 1769.
Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials
  • Guosheng Yin
  • Zhao Yang
  • Motoi Odani
  • Satoru Fukimbara
Statistics in Biopharmaceutical Research (2021) 13 (2): 248.
Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential
  • Michael J. Grayling
  • Theophile Bigirumurame
  • Svetlana Cherlin
  • Luke Ouma
  • Haiyan Zheng
  • James M. S. Wason
BMC Rheumatology (2021) 5 (1)
A signature enrichment design with Bayesian adaptive randomization
  • Fang Xia
  • Stephen L. George
  • Jing Ning
  • Liang Li
  • Xuelin Huang
Journal of Applied Statistics (2021) 48 (6): 1091.
Estimating the distribution of heterogeneous treatment effects from treatment responses and from a predictive biomarker in a parallel‐group RCT: A structural model approach
  • Ruediger P. Laubender
  • Ulrich Mansmann
  • Michael Lauseker
Biometrical Journal (2020) 62 (3): 697.
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer
  • Benjamin Dizier
  • Andrea Callegaro
  • Muriel Debois
  • Brigitte Dreno
  • Peter Hersey
  • Helen J. Gogas
  • John M. Kirkwood
  • Johan F. Vansteenkiste
  • Lecia V. Sequist
  • Djordje Atanackovic
  • Jelle Goeman
  • Hans van Houwelingen
  • Susana Salceda
  • Fawn Wang
  • Patrick Therasse
  • Channa Debruyne
  • Bart Spiessens
  • Vincent G. Brichard
  • Jamila Louahed
  • Fernando Ulloa-Montoya
Clinical Cancer Research (2020) 26 (7): 1725.
Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials
  • Joachim Theilhaber
  • Marielle Chiron
  • Jennifer Dreymann
  • Donald Bergstrom
  • Jack Pollard
BMC Bioinformatics (2020) 21 (1)
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs
  • Thomas Burnett
  • Pavel Mozgunov
  • Philip Pallmann
  • Sofia S. Villar
  • Graham M. Wheeler
  • Thomas Jaki
BMC Medicine (2020) 18 (1)
Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores
  • Svetlana Cherlin
  • James M. S. Wason
Statistics in Medicine (2020) 39 (24): 3285.
Multi-stage adaptive enrichment trial design with subgroup estimation
  • Neha Joshi
  • Crystal Nguyen
  • Anastasia Ivanova
Journal of Biopharmaceutical Statistics (2020) 30 (6): 1038.
The acute respiratory distress syndrome biomarker pipeline: crippling gaps between discovery and clinical utility
  • Christian Bime
  • Sara M. Camp
  • Nancy Casanova
  • Radu C. Oita
  • Juliet Ndukum
  • Heather Lynn
  • Joe G.N. Garcia
Translational Research (2020) 226: 105.
Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documents
  • Masahiro Tohkin
  • Yoshiro Saito
  • Satomi Yagi
  • Kunihito Asano
  • Keiko Maekawa
  • Makoto Osabe
  • Shinsuke Iida
  • Naoki Miyata
Drug Metabolism and Pharmacokinetics (2020) 35 (2): 187.
Bayesian Incentive-Compatible Bandit Exploration
  • Yishay Mansour
  • Aleksandrs Slivkins
  • Vasilis Syrgkanis
Operations Research (2020) 68 (4): 1132.
On the Use of Marker Strategy Design to Detect Predictive Marker Effect in Cancer Immunotherapy and Targeted Therapy
  • Yan Han
  • Ying Yuan
  • Sha Cao
  • Muyi Li
  • Yong Zang
Statistics in Biosciences (2020) 12 (2): 180.
Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment
  • Ting Wang
  • Xiaofei Wang
  • Stephen L George
  • Haibo Zhou
Journal of Biopharmaceutical Statistics (2020) 30 (6): 1060.
Review of Statistical Methods for Biomarker-Driven Clinical Trials
  • Richard Simon
JCO Precision Oncology (2019) (3): 1.
Two‐stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers
  • Yong Lin
  • Weichung J. Shih
  • Shou‐En Lu
Statistics in Medicine (2019) 38 (29): 5445.
Futility for subgroup analyses in the adaptive signature design
  • Andrea Callegaro
Statistical Methods in Medical Research (2019) 28 (3): 953.
Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design
  • Arinjita Bhattacharyya
  • Shesh N. Rai
Contemporary Clinical Trials Communications (2019) 15: 100378.
Finding the intended use population for a new treatment
  • Richard Simon
  • Noah Simon
Journal of Biopharmaceutical Statistics (2019) 29 (4): 675.
Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation
  • Mei-Yin C. Polley
  • Edward L. Korn
  • Boris Freidlin
JCO Precision Oncology (2019) (3): 1.
CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial
  • Fangqi Liu
  • Tong Tong
  • Dan Huang
  • Weitang Yuan
  • Dechuan Li
  • Jianjiang Lin
  • Sanjun Cai
  • Ye Xu
  • Wenbin Chen
  • Yueming Sun
  • Jing Zhuang
BMJ Open (2019) 9 (1): e017637.
Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations
  • Chen Hu
  • James J. Dignam
JCO Precision Oncology (2019) (3): 1.
Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker
  • Neha Joshi
  • Jason Fine
  • Rong Chu
  • Anastasia Ivanova
Journal of Biopharmaceutical Statistics (2019) 29 (4): 685.
Personalized Cancer Genomics
  • Richard M. Simon
Annual Review of Statistics and Its Application (2018) 5 (1): 169.
Development of predictive signatures for treatment selection in precision medicine with survival outcomes
  • Yu‐Chuan Chen
  • Un Jung Lee
  • Chen‐An Tsai
  • James J. Chen
Pharmaceutical Statistics (2018) 17 (2): 105.
Auto-adaptive Alpha Allocation: A Strategy to Mitigate Risk on Study Assumptions
  • Yue Shentu
  • Cong Chen
  • Lei Pang
  • Robert A. Beckman
Statistics in Biosciences (2018) 10 (2): 342.
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
  • Brigitte Dreno
  • John F Thompson
  • Bernard Mark Smithers
  • Mario Santinami
  • Thomas Jouary
  • Ralf Gutzmer
  • Evgeny Levchenko
  • Piotr Rutkowski
  • Jean-Jacques Grob
  • Sergii Korovin
  • Kamil Drucis
  • Florent Grange
  • Laurent Machet
  • Peter Hersey
  • Ivana Krajsova
  • Alessandro Testori
  • Robert Conry
  • Bernard Guillot
  • Wim H J Kruit
  • Lev Demidov
  • John A Thompson
  • Igor Bondarenko
  • Jaroslaw Jaroszek
  • Susana Puig
  • Gabriela Cinat
  • Axel Hauschild
  • Jelle J Goeman
  • Hans C van Houwelingen
  • Fernando Ulloa-Montoya
  • Andrea Callegaro
  • Benjamin Dizier
  • Bart Spiessens
  • Muriel Debois
  • Vincent G Brichard
  • Jamila Louahed
  • Patrick Therasse
  • Channa Debruyne
  • John M Kirkwood
The Lancet Oncology (2018) 19 (7): 916.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept